A5087019685- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Esophageal Cancer Research and Treatment
- Medical Imaging Techniques and Applications
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Cancer Cells and Metastasis
- Breast Lesions and Carcinomas
- Radiopharmaceutical Chemistry and Applications
- Ferroptosis and cancer prognosis
- BRCA gene mutations in cancer
- DNA Repair Mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Biotin and Related Studies
- Genetics, Bioinformatics, and Biomedical Research
- Bioinformatics and Genomic Networks
- Ethics in Clinical Research
- Linguistic research and analysis
- Metastasis and carcinoma case studies
- PARP inhibition in cancer therapy
LVR-Klinik für Orthopädie Viersen
2015-2024
Institute for Research Information and Quality Assurance
2024
Hospital Clínic de Barcelona
2019
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2019
Medizinische Hochschule Hannover
2011-2019
Ludwig-Maximilians-Universität München
2013-2018
Breast Center
2010-2018
Women‘s Healthcare Group
2013-2016
Universität Hamburg
2016
University Medical Center Hamburg-Eppendorf
2016
Invasive lobular breast carcinoma (ILC) is the second most common (BC) subtype and mainly driven by loss of E-cadherin expression. Correct classification BC as ILC important for patient treatment. This study assessed degree agreement among pathologists diagnosis ILC. Two sets hormone receptor (HR)-positive/HER2-negative BCs were independently reviewed participating pathologists. In set A (61 cases), participants provided with hematoxylin/eosin (HE)-stained sections. B (62 HE-stained sections...
Anthracycline-containing neoadjuvant chemotherapy (NACT) is the standard treatment for early triple-negative breast cancer (eTNBC); however, it associated with substantial toxicity. We performed whole transcriptome profiling of baseline tumor biopsies to identify gene networks predictive and prognostic pathological complete response (pCR) survival after de-escalated, anthracycline-free NACT in WSG-ADAPT-TN trial (NCT01815242). eTNBC patients (cT1c-cT4c, cN +) were randomized 12 weeks...
In the neoadjuvant WSG-ADAPT-TN trial, 12-week nab-paclitaxel + carboplatin (nab-pac/carbo) was highly effective and superior to gemcitabine (nab-pac/gem) in triple-negative breast cancer regarding pathological complete response (pCR). Predictive markers for deescalated taxane/carbo use TNBC need be identified. Patients received 4 × nab-pac 125 mg/m2 (plus carbo AUC2 or gem 1,000 d1,8 q21). Expression of 119 genes PAM50 scores by nCounter were available 306/336 pretherapeutic samples....
Purpose: The West German Study Group (WSG) Breast Cancer Intrinsic Subtype (BCIST) study was designed to assess the influence of Prosigna gene signature assay results on physicians' adjuvant treatment recommendations by determining extent change in pre-test following results. Secondary objectives were confidence their therapeutic and patients' decisional conflict status, anxiety levels, functional status. Methods: This prospective, observational, decision impact enrolled consecutive...
Abstract Recently, a new variant of invasive lobular breast cancer (ILBC) with solid‐papillary‐like growth pattern has been described. We present case ILBC in the main tumour mass and classical adjacent satellite foci. The two components were subjected to comprehensive molecular analyses. Both ER/PR‐positive, HER2‐negative, showed complete loss E‐cadherin beta‐catenin protein expression, as determined by immunohistochemistry. Gene expression profiling classified focus luminal‐B luminal‐A...
503 Background: Optimal use of de-escalated, particularly chemotherapy(CT)-free, neoadjuvant regimens in HER2+ early breast cancer (EBC) is currently unclear as there are limited survival data so far. In ADAPT-HR-/HER2+, we previously showed an excellent pCR rate 90% after 12-week paclitaxel (Pac) +pertuzumab (P) +trastuzumab (T) and a substantial clinically meaningful 34% P+T alone HR-/HER2+ EBC. Here, present first data. Methods: The prospective multicenter WSG-ADAPT-HR-/HER2+ phase...
BRCA1 is an important protein in the repair of DNA double strand breaks (DSBs), which are induced by alkylating chemotherapy. A BRCA1-like copy number signature derived from tumors with a mutation indicative for impaired function and associated good outcome after high dose (HD) tandem HD DSB inducing We investigated whether status was predictive biomarker WSG AM 01 trial. randomized high-risk breast cancer patients to induction (2× epirubicin-cyclophosphamide) followed chemotherapy...
Abstract Background: Pathological complete response (pCR) is associated with improved prognosis in TNBC, but optimal chemotherapy remains unclear. Use of weekly nab- paclitaxel (Nab-Pac) vs. conventional and also addition carboplatinum(Carbo) to anthracycline-taxane(A/T) containing results significantly higher pCR rates TNBC unclear impact on survival increased toxicity. The ADAPT study seeks compare Carbo gemcitabine(Gem) added as a short 12-week A-free regimen. It assesses efficacy early...
In intermediate risk hormone receptor (HR) positive, HER2 negative breast cancer (BC), the decision regarding adjuvant chemotherapy might be facilitated by multigene expression tests. all, 142 BCs were investigated using PAM50-based test Prosigna® in a prospective multicentric study. 119/142 cases, molecular subtyping was compared with local and two central (C1 C6) molecular-like subtypes relying on both immunohistochemistry (IHC; HRs, HER2, Ki-67) IHC + tumor grade (IHC+G) subtyping....
590 Background: pCR successfully identified candidates for (chemotherapy) de-escalation in the ADAPT HER2+ trial program. Here, we report biomarker analysis single arm, hypothesis-generating Keyriched-1 (NCT03988036) HER2-E eBC treated with pembrolizumab and dual HER2 blockade. The rationale is based on high efficacy of anti-HER2 agents potentially immunogenicity immune checkpoint protein expression eBC. Methods: 48 patients 2+ (ISH+) or 3+ (stage I-III) subtype received (200 mg),...
Abstract Background: De-escalating strategies seem promising in HER2-positive early breast cancer (EBC) and chemo-free regimens are thus of key interest. Recent data have underlined the role tumor immunogenicity response to de-escalated neoadjuvant anti-HER2 therapy. Therefore, prospective single arm hypothesis-generating phase II KEYRICHED-1 trial (NCT03988036) investigates pCR-rate patients with HER2-enriched EBC receiving four cycles dual blockade combination checkpoint inhibitor...
Abstract Background:Immune markers such as tumor infiltrating lymphocytes (TILs), CD8, PDL1, PD1 and other protein or mRNA-based genomic have been identified prognostic / predictive in TNBC regarding survival chemotherapy (CTx) efficacy. In the adjuvant WSG-PlanB trial, patients with high TILs and/or CD8 by mRNA had excellent outcome, irrespective of anthracycline use; neoadjuvant ADAPT-TN were for pCR. Still, optimal potential treatment de-escalation yet to be determined. Here, we analyse...
Abstract Purpose: To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) survival in the Phase II WSG-ADAPT HER2+/HR− trial (NCT01817452). Experimental Design: Patients cT1-cT4c, cN0–3 early breast cancer (EBC) were randomized to pertuzumab+trastuzumab (P+T, n = 92) or P+T+paclitaxel (n 42). Gene expression analyzed baseline biopsies using NanoString Breast Cancer 360 panel 117); on-treatment...
535 Background: Prosigna is a standardized test measuring expression levels of 50 classifier genes (PAM50) in formalin-fixed, paraffin-embedded (FFPE) breast tumor tissue using nCounter Technology (NanoString Technologies, Inc., Seattle, WA). It provides intrinsic subtype and risk recurrence (ROR) score predicting 10y probability. was retrospectively validated by ABCSG 8 TransATAC. WSG BCIST evaluates its impact on systemic therapy decisions EBC. Methods: 201 consecutive postmenopausal pts....
Tumor biological factors of breast cancer (BC) such as hormone receptor (HR) status, HER2 and grade can differ in the metastatic cascade from primary to lymph node (LN) metastasis distant tissue. Systematic data regarding therapeutic consequences are yet limited.We conducted a prospectively planned, retrospective cohort study comparing BC phenotype tissue tumors (PTs), locoregional LN metastases, disease recurrence (DR). HR well tumor PTs DR were obtained by database search. No centralized...
11018 Background: DNA copy number profiles identify patients with a defect in BRCA1 associated homologous recombination repair defect. We previously showed that BRCA1-like profile benefit from high-dose (HD) and tandem HD chemotherapy (CT) (carboplatin/thiotepa/cyclophosphamide; ifosfamide/epirubicin/carboplatin). WSG AM-01 trial reported superiority of vs. dose-dense CT high-risk BC patients. Subgroup analysis attributed this effect to triple-negative BC. Methods: Phase III randomized 403...
Abstract Background ctDNA testing is emerging as an important biomarker in early breast cancer (eBC). However, its value prediction of tumor response to de-escalated, chemotherapy-free neoadjuvant therapy (NAT) remains underexplored. In WSG-Keyriched-1 (NCT03988036), a single-arm phase 2 trial, we investigated for the first time NAT with dual HER2 blockade and pembrolizumab HER2- enriched HER2+ eBC. this pre-specified translational analysis, evaluated whether measurement could predict pCR....
Abstract Background Introduction of anti-HER2 therapies substantially improved outcomes for HER2-positive early breast cancer (HER2+ eBC). However, a considerable proportion patients (pts) may still be overtreated with systemic chemotherapy (CTx) combinations. Establishing safe de-escalation strategies to avoid toxicities requires precise patient selection. Therefore, we set out determine predictors efficacy and survival in the unique setting four trials investigating short (12-week)...
573 Background: In the ADAPT-TN neoadjuvant trial, 12-week nab-paclitaxel (nab- pac)+carboplatin (carbo) was highly effective and superior to nab-pac+gemcitabine (gem). However, within TNBC, reliable predictive markers for carbo use have yet be identified. Methods: Patients with early TNBC (centrally confirmed) were treated by nab-pac 125 mg/m2 either AUC2 or gem 1000 d 1,8 q21 given 4 cycles. Genomic data (80 genes) Prosigna (PAM-50) scores available in 306 pre-therapeutic samples of 331...